Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Development and clinical evaluation of a cost-effective method with capillary electrophoresis sequencer-based fragment analysis assay panel for genetic classification and risk stratification in de novo AML

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKohei MorimotoKYKimikazu Yakushijin

Discussion

Loading...

Member takes

Overview

Clinical evaluation shows cost-effective fragment analysis for genetic classification and mutation detection in AML, indicating improved risk stratification.

Key Points

  • 100% accuracy achieved in mutation detection using capillary electrophoresis compared to Sanger sequencing, confirming reliability.
  • Mutation analysis included FLT3-ITD mutations, with subtypes identified in multiple sizes, enhancing diagnostic capability.
  • Capillary electrophoresis method allows rapid, sensitive detection of key mutations, important for prognosis in de novo AML.
  • Risk stratification can now be performed cost-effectively, promoting better treatment decisions in diverse clinical settings.

Cite This Study

Morimoto et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc24https://doi.org/10.1182/blood-2025-7854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  2. 2Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model2025
  3. 3Sensitive detection of novel structural variants and 3D chromosome conformation reveals likely novel drivers including enhancer hijacking in AML2025
  4. 4Comparative evaluation of NGS-based MRD detection in AML using longitudinal matched bone marrow and blood samples2025
  5. 5Interrogation of a large clinical data cohort derived from a comprehensive panheme NGS-based assay for elucidation into MDS risk stratification, impact of chip on disease, biopsy sensitivity, and MRD evaluation2025